WO2023007399 - ANTIMICROBIAL COMPOSITIONS COMPRISING EDTA, ALCOHOL AND CHLORHEXIDINE AND USE THEREOF ON BIOFILMS CELLS
National phase entry is expected:
Publication Number
WO/2023/007399
Publication Date
02.02.2023
International Application No.
PCT/IB2022/056951
International Filing Date
27.07.2022
Title **
[English]
ANTIMICROBIAL COMPOSITIONS COMPRISING EDTA, ALCOHOL AND CHLORHEXIDINE AND USE THEREOF ON BIOFILMS CELLS
[French]
COMPOSITIONS ANTIMICROBIENNES COMPRENANT DE L'EDTA, DE L'ALCOOL ET DE LA CHLORHEXIDINE ET LEUR UTILISATION SUR DES CELLULES DE BIOFILMS
Applicants **
STERILECARE INC.
15 Allstate Parkway, Suite 600
Markham, Ontario L3R 5B4, CA
Inventors
MUELLER, Karen
15 Allstate Parkway, Suite 600
Markham, Ontario L3R 5B4, CA
Priority Data
63/226,109
27.07.2021
US
111128029
26.07.2022
TW
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1661 | |
| EPO | Filing, Examination | 11776 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 4910 |
Total: 19547 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides compositions, methods of preparing, and method of use of a composition comprising: (a) about 0.05 wt% to about 10.0 wt% ethylenediamaminetetraacetic acid, a salt thereof, a chelating agent, or a combination thereof; (b) from about 2.0 wt% to 50.0 wt% ethanol (ET), isopropyl alcohol (IP A), or a combination thereof; and (c) from about 0.015 µg/mL to about 100.0 µg/mL chlorhexidine, a salt thereof, or a combination thereof. These compositions, as disclosed herein, eliminate greater the 95% of planktonic or biofilm cells from a central venous access device.[French]
La présente invention concerne des compositions, des procédés de préparation et un procédé d'utilisation d'une composition comprenant : (a) environ 0,05 % en poids à environ 10,0 % en poids d'acide éthylènediaminetétracétique, d'un sel de celui-ci, d'un agent chélateur, ou d'une combinaison de ceux-ci ; (b) d'environ 2,0 % en poids à 50,0 % en poids d'éthanol (ET), d'alcool isopropylique (AIP), ou d'une combinaison de ceux-ci ; et (c) d'environ 0,015 |jg/ml à environ 100,0 |jg/ml de chlorhexidine, d'un sel de celle-ci, ou d'une combinaison de ceux-ci. Ces compositions, telles que décrites dans le présent document, éliminent plus de 95 % des cellules planctoniques ou du biofilm d'un dispositif d'accès veineux central.